Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis
NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases
About This Grant
Project Summary/Abstract Psoriatic arthritis is a chronic and progressive inflammatory arthritis closely linked with psoriasis. Blockade of the IL-17 signaling pathway shows impressive efficacy and excellent safety for treatment of psoriasis but less so for PsA. Tissue penetrance limits the bioavailability of monoclonal antibodies to the joint and fibrocartilaginous enthesis and IL-17A signaling is diversified by local immune cells in tissues rendering IL-17A inhibition less effective. A higher dosage poses the risks of serious infections and certain types of cancer as all IL-17 inhibitors are immunosuppressive therefore to improve clinical outcomes in PsA more selective targeting is required. Herein, we have developed a novel animal model of IL-17A gene transfer where mice develop joint and skin inflammation associated with enthesitis, fingernail psoriasis and onycholysis hallmarks of PsA pathology. We will interrogate our murine model to define the early cellular and molecular pathways that dictate IL-17A-induced pathologies using state-of-the-art transgenic mice and molecular tools. Our work will uncover the pathogenic mechanisms of IL-17A and uncover novel molecular targets that can be exploited for therapeutic intervention and directly benefit PsA patients worldwide.
Grant Summary
Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis is a NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases grant providing up to $568K for university, nonprofit, healthcare org. Applications are due 2030-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $568K
2030-03-31
- 1Confirm your organization is eligible for Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis from NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis: Frequently Asked Questions
Who is eligible for the Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis?
Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis is offered by NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis provide?
Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis provides up to $568K per award from NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis deadline?
Applications for Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis are due 2030-03-31 (open). Because deadlines can change, verify the date with the funder, NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis?
To apply for Cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases.